Across TCGA pan-cancer cohorts, STATH Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated STATH data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher STATH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STATH expression acts as an unfavorable survival marker.
LGG are the cancer types where STATH Mutation most reproducibly stratifies survival.